---
title: "Medtronic Announces Groundbreaking Results from ADAPT-PD Trial, Showcasing Effectiveness of BrainSense™ Adaptive DBS for Parkinson's Patients"
description: "Medtronic plc has published results from the ADAPT-PD trial in JAMA Neurology, showcasing the effectiveness of its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson’s disease. This pivo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258389070.md"
published_at: "2025-09-22T15:24:13.000Z"
---

# Medtronic Announces Groundbreaking Results from ADAPT-PD Trial, Showcasing Effectiveness of BrainSense™ Adaptive DBS for Parkinson's Patients

> Medtronic plc has published results from the ADAPT-PD trial in JAMA Neurology, showcasing the effectiveness of its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson’s disease. This pivotal trial, the largest of its kind, involved leading neurologists and neurosurgeons across 10 centers in the U.S., Canada, and Europe, marking a significant advancement in managing Parkinson’s disease through closed-loop neuromodulation technology.

Medtronic plc has announced the publication of results from the Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial in the Journal of the American Medical Association (JAMA) Neurology. The trial assessed the chronic use of the BrainSense™ Adaptive deep brain stimulation (aDBS) for individuals with Parkinson’s disease. This pivotal trial, the largest and longest of its kind, evaluated the effectiveness of closed-loop neuromodulation. Conducted globally, it involved leading neurologists and neurosurgeons across 10 centers in the United States, Canada, and Europe. The study marks a significant advancement in managing Parkinson’s disease, leveraging BrainSense™ technology to develop an adaptive DBS system that detects and classifies different brain signals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MDT.US - Medtronic](https://longbridge.com/en/quote/MDT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Medtronic Wins FDA Approval for Expanded Deep Brain Stimulation Labeling for Dystonia | Medtronic plc has received FDA approval for expanded labeling of its Deep Brain Stimulation system for treating dystonia | [Link](https://longbridge.com/en/news/268630733.md) |
| Medtronic's Renal Denervation Procedure 'Significantly' Reduces Blood Pressure After 3 Years | Medtronic's Renal Denervation Procedure 'Significantly' Reduces Blood Pressure After 3 Years | [Link](https://longbridge.com/en/news/262838805.md) |
| Dr. Patrick F. Doherty Recognized for Three Decades of Leadership in Advanced Neurosurgery and Patient Centered Care in Connecticut | Dr. Patrick F. Doherty, a leading neurosurgeon in Connecticut, has been recognized for over 30 years of excellence in ne | [Link](https://longbridge.com/en/news/275792535.md) |
| Neumora Therapeutics unveils new pipeline targeting neuropsychiatric and metabolic diseases | Neumora Therapeutics Inc. has unveiled a new pipeline focused on neuroscience drug development, targeting neuropsychiatr | [Link](https://longbridge.com/en/news/275602847.md) |
| PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents \| PRVCF Stock News | PreveCeutical Medical Inc. has filed an International (PCT) patent application for innovative methods to deliver CNS-act | [Link](https://longbridge.com/en/news/275283423.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.